Effects of Pegylated Interferon α on Fibrinolytic Parameters in Patients With Chronic Hepatitis C
| Autor: | Yucel Ustundag, Hüseyin Engin, Ayla Gökmen, Nefise Oztoprak, Ishak Ozel Tekin, Sibel Kiran, Selim Aydemir, Basak Cakal |
|---|---|
| Přispěvatelé: | Zonguldak Bülent Ecevit Üniversitesi |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Carboxypeptidase B2 medicine.medical_specialty Time Factors medicine.medical_treatment Alpha interferon Antiviral Agents Tissue plasminogen activator Gastroenterology Fibrin Fibrinogen Degradation Products chemistry.chemical_compound Interferon Internal medicine Plasminogen Activator Inhibitor 1 Ribavirin Fibrinolysis Euglobulin lysis time medicine Humans Aged business.industry Interferon-alpha interferon Hematology General Medicine Hepatitis C Chronic Middle Aged chronic viral hepatitis chemistry Tissue Plasminogen Activator Plasminogen activator inhibitor-1 Immunology Female fibrinolysis business Plasminogen activator medicine.drug |
| Zdroj: | Clinical and Applied Thrombosis/Hemostasis. 17:449-453 |
| ISSN: | 1938-2723 1076-0296 |
| DOI: | 10.1177/1076029610371475 |
| Popis: | WOS: 000295613900002 PubMed: 20699259 Interferon (IFN) interacts with endothelial cells and modulates the functions of these cells. In our study, we aimed to determine the effects of treatment with pegylated IFN-alpha (peg-IFN-alpha) on fibrinolytic parameters in patients with chronic hepatitis C. Fifteen patients with chronic hepatitis C were treated with peg-IFN-a once per week plus daily oral ribavirin. Euglobulin lysis time (ELT), plasma levels of D-dimer, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined before treatment, 2 weeks, 1 month, and 3 months after the initiation of the treatment. Plasma levels of t-PA increased significantly 1 month and 3 months after the treatment (P < .05). The PAI-1 and TAFI levels in 2 weeks, 1 month and 3 months after treatment were not statistically different as compared with pretreatment levels (P > .05) No significant difference in plasma D-dimer levels was observed during peg-IFN-alpha treatment (P > .05). There was a significant decrease in ELT 1 month and 3 months after the treatment (P < .05). Our results indicated that treatment with peg-IFN-alpha may be associated with enhanced fibrinolysis |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|